Managing Editor, US Commercial News
+20 year(s) experience
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Gilead is negotiating Sovaldi’s (sofosbuvir) pricing with the Chinese government. This is a necessary step to ensure the company captures China’s large hepatitis C population, following its decision to exclude the country from its drug access program, and to also avoid the potential negative repercussions in other emerging markets should China resort to compulsory licensing.
Topic Drug approval